Qiagen (NYSE:QGEN) Releases FY 2026 Earnings Guidance

Qiagen (NYSE:QGEN) updated its FY 2026 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 2.430- for the period, compared to the consensus earnings per share estimate of 2.430. The company issued revenue guidance of $2.1 billion-$2.1 billion, compared to the consensus revenue estimate of $2.2 billion.

Analysts Set New Price Targets

Several brokerages have recently commented on QGEN. JPMorgan Chase & Co. lowered their price objective on Qiagen from $60.00 to $45.00 and set an “overweight” rating for the company in a research note on Wednesday, April 29th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $43.00 price target on shares of Qiagen in a report on Thursday, April 30th. Stifel Nicolaus set a $36.00 price target on Qiagen and gave the company a “hold” rating in a report on Monday, May 18th. Citigroup reaffirmed a “hold” rating on shares of Qiagen in a research note on Monday, May 18th. Finally, Kepler Capital Markets set a $38.60 target price on shares of Qiagen and gave the stock a “hold” rating in a report on Thursday, June 25th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Qiagen has an average rating of “Hold” and a consensus price target of $43.34.

Qiagen Stock Performance

Qiagen stock traded down $0.40 during mid-day trading on Wednesday, reaching $41.93. 2,037,433 shares of the stock traded hands, compared to its average volume of 2,895,016. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.21 and a quick ratio of 2.57. Qiagen has a 12-month low of $32.53 and a 12-month high of $57.81. The stock has a market capitalization of $8.64 billion, a PE ratio of 21.90, a price-to-earnings-growth ratio of 4.22 and a beta of 0.63. The business’s 50-day moving average is $39.21 and its 200-day moving average is $41.73.

Qiagen (NYSE:QGEN) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.62 earnings per share for the quarter, beating analysts’ consensus estimates of $0.60 by $0.02. Qiagen had a return on equity of 14.40% and a net margin of 19.16%.During the same quarter in the previous year, the company posted $0.60 EPS. The company’s revenue was up .2% compared to the same quarter last year. Qiagen has set its FY 2026 guidance at 2.430- EPS. As a group, sell-side analysts predict that Qiagen will post 2.43 EPS for the current fiscal year.

Qiagen Increases Dividend

The company also recently announced an annual dividend, which was paid on Tuesday, July 14th. Stockholders of record on Tuesday, July 7th were paid a $0.35 dividend. This is an increase from Qiagen’s previous annual dividend of $0.26. This represents a dividend yield of 90.0%. The ex-dividend date of this dividend was Tuesday, July 7th. Qiagen’s payout ratio is currently 18.32%.

Hedge Funds Weigh In On Qiagen

A number of large investors have recently bought and sold shares of QGEN. Danske Bank A S acquired a new position in Qiagen during the 3rd quarter valued at about $36,000. Global Retirement Partners LLC grew its position in Qiagen by 279.9% during the 4th quarter. Global Retirement Partners LLC now owns 1,155 shares of the company’s stock worth $52,000 after purchasing an additional 851 shares during the period. Advisory Services Network LLC acquired a new position in Qiagen in the third quarter valued at approximately $64,000. Kestra Advisory Services LLC acquired a new position in shares of Qiagen in the 4th quarter valued at $70,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in shares of Qiagen during the 4th quarter worth about $73,000. Institutional investors own 70.00% of the company’s stock.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library?preparation kits and proteomics solutions.